Nosocomial outbreak of New Delhi metalloβ-lactamase-1-producing Gram-negative bacteria in South Africa: A case-control study

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  De Jager, Pieter ^a,b   Chirwa, Tobias ^b   Naidoo, Shan ^b   Perovic, Olga ^c,d   Thomas, Juno ^c  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; DORIPENEM; ERTAPENEM; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; METALLO BETA LACTAMASE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TOBRAMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE NDM-1;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOODSTREAM INFECTION; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; GRAM NEGATIVE BACTERIUM; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICA; VERY ELDERLY; BIOSYNTHESIS; CROSS INFECTION; EPIDEMIC; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; ODDS RATIO; YOUNG ADULT;

KLEBSIELLA PNEUMONIAE; NEGIBACTERIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CASE-CONTROL STUDIES; CROSS INFECTION; DISEASE OUTBREAKS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SOUTH AFRICA; YOUNG ADULT;

EID: 84929302833     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123337     Document Type: Article

References (35)

1. st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin Microbiol Rev. 2001; 14: 933-951. doi: 10.1128/CMR.14.4.933-951.2001 PMID: 11585791
2. Jacoby GA, Munoz-Price LS. The new β-lactamases. New England Journal of Medicine. 2005; 352: 380-391. PMID: 15673804
3. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clinical Microbiology and Infection. 2002; 8: 321-331. doi: 10.1046/j.1469-0691.2002.00401.x PMID: 12084099
4. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant enterobacteriaceae: epidemiology and prevention. Clinical infectious diseases. 2011; 53: 60. doi: 10.1093/cid/cir202 PMID: 21653305
5. st Century - A Clinical Super-Challenge. New England Journal of Medicine. 2009; 360: 439-443. doi: 10.1056/NEJMp0804651 PMID: 19179312
6. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001; 45: 1151-1161. doi: 10.1128/AAC.45.4.1151-1161.2001 PMID: 11257029
7. Brink AJ, Coetzee J, Clay CG, Sithole S, Richards GA, Poirel L, et al. Emergence of New Delhi metallobeta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa. Journal of Clinical Microbiology. 2012; 50: 525-527. doi: 10.1128/JCM.05956-11 PMID: 22116157
8. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol. 2011; 19: 588-595. doi: 10.1016/j.tim.2011.09.005 PMID: 22078325
9. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009; 64: i29-i36. doi: 10.1093/jac/dkp255 PMID: 19675016
10. Bonomo RA. New Delhi Metallo-β-Lactamase and Multidrug Resistance: A Global SOS? Clin Infect Dis. 2011; 52: 485-487. doi: 10.1093/cid/ciq179 PMID: 21258101
11. Molton JS, Tambyah PA, Ang BSP, Ling ML, Fisher DA. The Global Spread of Healthcare-Associated Multidrug-Resistant Bacteria: A Perspective From Asia. Clin Infect Dis. 2013; 56: 1310-1318. doi: 10.1093/cid/cit020 PMID: 23334810
12. Moellering RC Jr. NDM-1 - a cause for worldwide concern. New England Journal of Medicine. 2010; 363: 2377-2379. doi: 10.1056/NEJMp1011715 PMID: 21158655
13. Walsh TR. Emerging carbapenemases: a global perspective. International Journal of Antimicrobial Agents. 2010; 36, Supplement 3: S8-S14. doi: 10.1016/S0924-8579(10)70004-2
14. Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum β-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother. 2011; 66: 689-692. doi: 10.1093/jac/dkq520 PMID: 21393184
15. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases. 2010; 10: 597-602. doi: 10.1016/S1473-3099(10)70143-2 PMID: 20705517
16. Nordmann P, Couard J-P, Sansot D, Poirel L. Emergence of an Autochthonous and Community-Acquired NDM-1-Producing Klebsiella pneumoniae in Europe. Clin Infect Dis. 2012; 54: 150-151. doi: 10.1093/cid/cir720 PMID: 21960718
17. Marais E, Moodley A, Govender N, Kularatne R, Thomas J, Duse A. Clusters of Klebsiella pneumoniae infection in neonatal intensive care units in Gauteng: scientific letter. South African Medical Journal. 2006; 96: p-813. PMID: 17068651
18. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American journal of infection control. 2008; 36: 309-332. doi: 10.1016/j.ajic.2008.03.002 PMID: 18538699
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases. 1987; 40: 373-383. PMID: 3558716
20. Higgins TL, Teres D, Copes WS, Nathanson BH, Stark M, Kramer AA. Assessing contemporary intensive care unit outcome: An updated Mortality Probability Admission Model (MPM0-III)∗. Critical care medicine. 2007; 35: 827-835. PMID: 17255863
21. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. Journal of clinical microbiology. 1995; 33: 2233. PMID: 7494007
22. Struelens MJ, Monnet DL, Magiorakos AP, Santos O'Connor F, Giesecke J. New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill. 2010; 15. Available: http://www.ncbi.nlm.nih.gov/pubmed/21144431
23. Borgia S, Lastovetska O, Richardson D, Eshaghi A, Xiong J, Chung C, et al. Outbreak of Carbapenem-Resistant Enterobacteriaceae Containing blaNDM-1, Ontario, Canada. Clin Infect Dis. 2012; doi: 10.1093/cid/cis737
24. Lowe CF, Kus JV, Salt N, Callery S, Louie L, Khan MA, et al. Nosocomial Transmission of New Delhi Metallo-β-Lactamase-1-Producing Klebsiella pneumoniae in Toronto, Canada. Infection Control and Hospital Epidemiology. 2013; 34: 49-55. doi: 10.1086/668778 PMID: 23221192
25. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality. Antimicrob Agents Chemother. 2008; 52: 1028-1033. doi: 10.1128/AAC.01020-07 PMID: 18086836
26. Tuon FF, Rocha JL, Toledo P, Arend LN, Dias CH, Leite TM, et al. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Braz J Infect Dis. 2012; 16: 416-419. doi: 10.1016/j.bjid.2012.08.006 PMID: 22980584
27. Hyle EP, Ferraro MJ, Silver M, Lee H, Hooper DC. Ertapenem-Resistant Enterobacteriaceae: Risk Factors for Acquisition and Outcomes. Infection Control and Hospital Epidemiology. 2010; 31: 1242-1249. doi: 10.1086/653029 PMID: 21029005
28. Gopi Patel M, Shirish Huprikar M, Stephanie H. Factor M MPH, Stephen G. Jenkins P, David P. Calfee M MS. Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies. Infection Control and Hospital Epidemiology. 2008; 29: 1099-1106. doi: 10.1086/596025 PMID: 18973455
29. Hirakata Y, Yamaguchi T, Nakano M, Izumikawa K, Mine M, Aoki S, et al. Clinical and Bacteriological Characteristics of IMP-Type Metallo-β-Lactamase-Producing Pseudomonas aeruginosa. Clin Infect Dis. 2003; 37: 26-32. doi: 10.1086/375594 PMID: 12830405
30. Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the Metallo-β-Lactamase Gene blaIMP-4 among Gram-Negative Pathogens in a Clinical Setting in Australia. Clin Infect Dis. 2005; 41: 1549-1556. doi: 10.1086/497831 PMID: 16267725
31. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early Dissemination of NDM-1- and OXA-181-Producing Enterobacteriaceae in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob Agents Chemother. 2011; 55: 1274-1278. doi: 10.1128/AAC.01497-10 PMID: 21189345
32. Szilágyi E, Füzi M, Damjanova I, Böröcz K, Szo{combining double acute accent}nyi K, Tóth á., et al. Investigation of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreaks in Hungary between 2005 and 2008. Acta Microbiologica et Immunologica Hungarica. 2010; 57: 43-53. doi: 10.1556/AMicr.57.2010.1.4 PMID: 20350878
33. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clinical Microbiology and Infection. 2011; 17: 1798-1803. doi: 10.1111/j.1469-0691.2011.03514.x PMID: 21595793
34. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48: 1-12. doi: 10.1086/595011 PMID: 19035777
35. Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria - Time to react is now. Drug Resistance Updates. 2011; 14: 118-124. doi: 10.1016/j.drup.2011.02.003 PMID: 21435939